Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability

Advanced Pharmaceutical Bulletin

Volumn 2, Issue 1, 2012, Pages 43-56

  Loveymi, Badir Delf ^a,b   Jelvehgari, Mitra ^a,c   Zakeri Milani, Parvin ^a,d   Valizadeh, Hadi ^a,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eudragit RS100; Nanoparticles; Physicochemical properties; Vncomycin

Indexed keywords

EUDRAGIT RS; NANOPARTICLE; VANCOMYCIN;

ABSORPTION; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DIFFERENTIAL SCANNING CALORIMETRY; DOUBLE EMULSION SOLVENT EVAPORATION METHOD; DRUG RELEASE; DRUG TO POLYMER RATIO; EMULSION; ENCAPSULATION; EVAPORATION; INFRARED SPECTROSCOPY; INTESTINE MUCOSA PERMEABILITY; MALE; MATERIAL COATING; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; RAT; SINGLE PASS INTESTINAL PERFUSION; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

EID: 84875912198     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2012.007     Document Type: Article

References (61)

1. Robles-Piedras AL, Gonz?lez-Lpez EH. Therapeutic Drug Monitoring of Vancomycin. Proc West Pharmacol Soc 2009;52:21-3.
2. Moellering RC Jr. Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There? Clinical infectious diseases 1994;18:544-6.
3. Cook FV, Farrar WE. Vancomycin revisited. Annals of internal medicine 1978; 88(6): 813-8.
4. Bryan CS, White WL. Safety of oral vancomycin in functionally anephric patients. Antimicrobial Agents and Chemotherapy 1978; 14(4): 634-35.
5. Geraci JE, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Antibiot Annu 1956-1957:90-106.
6. Florence AT. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug discovery today: technologies 2005; 2(1):75-81.
7. Yallapu MM, et al. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of colloid and interface science 2010; 351(1): 19-29.
8. Kumar GS, et al. Synthesis and characterization of bioactive hydroxyapatite-calcite nanocomposite for biomedical applications. Journal of colloid and interface science 2010; 349(1): 56-62.
9. Nouvel C, et al. Biodegradable nanoparticles made from polylactide-grafted dextran copolymers.Journal of colloid and interface science 2009; 330(2): 337-43.
10. Han DP, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. American journal of ophthalmology 1996; 122(1): 1-17.
11. Jelvehgari M, et al. Formulation, characterization and in vitro evaluation of theophylline-loaded Eudragit RS 100 microspheres prepared by an emulsion-solvent diffusion/evaporation technique. Pharmaceutical Development and Technology 2011;16:637-44.
12. Valizadeh H, et al. A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies. J AOAC Int 2006; 89(1): 88-93.
13. Zakeri-Milani,P, et al. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm 2009; 73(1): 102-6.
14. Zakeri-Milani P, et al. Investigation of the intestinal permeability of ciclosporin using the in situ technique in rats and the relevance of P-glycoprotein. Arzneimittelforschung 2008; 58(4): 188-92.
15. Zakeri-Milani P, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 2007; 10(3): 368-79.
16. Zakeri-Milani P, et al. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug Dev Ind Pharm 2009; 35(12): 1496-502.
17. Dashevsky A, Zessin G. The effect of ethylcellulose molecular weight on the properties of theophylline microspheres. Journal of microencapsulation 1997; 14(3): 273-80.
18. Saravanan M, et al. Ibuprofen-loaded ethylcellulose/polystyrene microspheres: an approach to get prolonged drug release with reduced burst effect and low ethylcellulose content. Journal of microencapsulation 2003; 20(3): 289-302.
19. Benichou A, Aserin A, Garti N. Polyols, high pressure, and refractive indices equalization for improved stability of W/O emulsions for food applications. Journal of dispersion science and technology 2001; 22(2-3): 269-80.
20. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical research 1996; 13(9): 1336-42.
21. Shantha Kumar TR, et al. Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and Phenol red in rat in situ intestinal perfusion study. Journal of pharmaceutical and biomedical analysis 2005; 38(1): 173-9.
22. Favetta P, et al. New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection. Journal of Chromatography B: Biomedical Sciences and Applications 2001; 751(2): 377-382.
23. Hoffart V, et al. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics. Drug Dev Ind Pharm 2002; 28(9): 1091-9.
24. Hasan AS, et al,.. Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int J Pharm 2007; 344(1-2): 53-61.
25. Couvreur P, et al. Nanocapsule technology: a review. Critical reviews in therapeutic drug carrier systems 2002; 19(2): 99-134.
26. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009; 5(1): 90-5.
27. Foster KA, Yazdanian M, Audus KL. Microparticulate uptake mechanisms of invitro cell culture models of the respiratory epithelium. Journal of pharmacy and pharmacology 2001, 53(1): 57-66.
28. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews 2001; 47(2-3): 165-96.
29. Mohanraj V, Chen Y. Nanoparticles-a review. Tropical Journal of Pharmaceutical Research 2007; 5(1): 561-73.
30. Govender T, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. Journal of Controlled Release 1999; 57(2): 171-85.
31. Govender T, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. International journal of pharmaceutics 2000; 199(1): 95-110.
32. Panyam J, et al .Solidstate solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. Journal of pharmaceutical sciences 2004; 93(7): 1804-14.
33. Gavini E, et al. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. European journal of pharmaceutics and biopharmaceutics 2004; 57(2): 207-12.
34. Mukherjee B, et al. A comparison between povidone-ethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. European journal of pharmaceutics and biopharmaceutics 2005; 59(3): 475-83.
35. Lin SY Yu HL. Microscopic fourier transform infrared/differential scanning calorimetry system used to study the different thermal behaviors of polymethacrylate copolymers of Eudragits RS, RL, E 30D, or E. Journal of applied polymer science 2000; 78(4): 829-35.
36. Gribb AA,Banfield JF. Particle size effects on transformation kinetics and phase stability in nanocrystalline TiO2. American Mineralogist 1997; 82(7): 717-28.
37. Kumar GS, et al. Synthesis and characterization of bioactive hydroxyapatite-calcite nanocomposite for biomedical applications. J Colloid Interface Sci 2010; 349(1): 56-62.
38. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342.
39. Amidon GL, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical research 1995; 12(3): 413-20.
40. Olfert ED, et al. Guide to the care and use of experimental animals. Vol. 1. 1993: Canadian Council on Animal Care Ottawa, Ontario, Canada.
41. Danzer L. Liquid-chromatographic determination of cephalosporins and chloramphenicol in serum. Clinical chemistry 1983; 29(5): 856-8.
42. Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharmaceutical research 1994; 11(8): 1132-42.
43. Youan BBC, et al. Protein release profiles and morphology of biodegradable microcapsules containing an oily core. Journal of controlled release 2001; 76(3): 313-26.
44. Pignatello R, et al. Properties of tolmetin-loaded Eudragit RL100 and Eudragit RS 100 microparticles prepared by different techniques. STP pharma sciences 1997;7(2): 148-57.
45. Malamataris S, Avgerinos A. Controlled release indomethacin microspheres prepared by using an emulsion solvent-diffusion technique. International Journal of Pharmaceutics 1990; 62(2-3): 105-11.
46. Alex R, Bodmeier R. Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment. Journal of Microencapsulation 1990; 7(3): 347-55.
47. Xie J, Wang CH. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharmaceutical research 2005; 22(12): 2079-90.
48. Ceschel G, et al. Degradation of components in drug formulations: a comparison between HPLC and DSC methods. Journal of pharmaceutical and biomedical analysis 2003; 32(4-5): 1067-72.
49. Jelvehgari M, et al. Control of encapsulation efficiency in polymeric microparticle system of tolmetin. Pharmaceutical development and technology 2010; 15(1): 71-9.
50. Aaltonen,J, et al. Polymorph screening using near-infrared spectroscopy. Analytical Chemistry 2003; 75(19): 5267-73.
51. Gupta M, Saini T. preformulation parameters characterization to design, development and formulation of vancomycin hydrochloride tablets for psudomembranous colitis. international Journal of pharmaceutical reaserch and development 2009; 1(9):1-7.
52. Jelvehgari M, et al. Preparation and Evaluation of Poly (-caprolactone) Nanoparticles-in-Microparticles by W/O/W Emulsion Method. Iranian Journal of Basic Medical Sciences 2010; 13(3): 1-8.
53. Capan Y, et al. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS Pharm Sci Tech 2003; 4(2): E28.
54. Yang YY, Chung TS, Ping Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001; 22(3): 231-41.
55. Wu JC, et al. Effect of the solvent-non-solvent pairs on the surface morphology and release behaviour of ethylcellulose microcapsules prepared by non-solvent-addition phase separation method. J Microencapsul 1994; 11(3): 297-308.
56. Wickramasinghe R, Liow JL, Leong YK. Nanobiotech congress. 2007; Available from: http://www.aiche.org/uploadedfiles/SBE/events/Tuesday07.pdf.
57. Martin A, Bustamante P, Chun AH. Physical Pharmacy and Pharmaceutical Sciences. Fifth edition ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
58. Mondal S, et al. Flocculation of yeast suspension by a cationic polymer: Characterization of flocculent-cell interaction. 2011. American Institute of Chemical Engineers.
59. Mukherjee B, et al. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine 2008; 3(4): 487-96.
60. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83(2): 273-86.
61. Ahlin P, et al. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 2002; 239(1-2): 113-20.